Thermo Fisher Closes Phadia Deal
Thermo Fisher Scientific Inc. has completed the acquisition of Phadia of Uppsala, Sweden, a provider of blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases.
Phadia now is part of Thermo Fisher’s Specialty Diagnostics business. The company is expected to contribute $0.07 to Thermo Fisher’s 2011 full-year adjusted earnings per share (EPS), an increase of $0.01 over the original estimate. Because of the favorable financing rates for the fourth quarter, the US company has adjusted its full-year EPS, which could result in a 20% to 23% EPS growth over 2010, it said.
In addition, Phadia is expected to add $190 million to the company’s 2011 revenue results, about a 12% growth in revenue over 2010.
For more information, visit:
www.thermofisher.com
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024